VCs: Venture funding grows, with more money for startups

John Carroll

That IPO boom was just what the VC doctor ordered. Between high-priced buyout deals and new offerings, the funds got the exits they needed to look good to investors and bring in fresh funds. This week we saw OrbiMed, a global player, close its $ 950 million fund, following Sofinnova Partners' $ 324 million play in Paris. And it's no surprise that they unveiled record sums.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS